Precision medicine for the treatment of triple negative breast cancer: opportunities and challenges

References

• Torre LA, Siegel RL, Ward EM, et al. Global cancer incidence and mortality rates and trends–an update. Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):16–27.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007 Aug;13(15 Pt 1):4429–4434.
   PubMed Web of Science ®Google Scholar
• Sihto H, Lundin J, Lundin M, et al. Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Res. 2011 Sep;13(5):R87.
   PubMed Web of Science ®Google Scholar
• Lin NU, Claus E, Sohl J, et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008 Nov;113(10):2638–2645.
   PubMed Web of Science ®Google Scholar
• Elsawaf Z, Sinn HP. Triple-negative breast cancer: clinical and histological correlations. Breast Care (Basel). 2011;6(4):273–278.
   PubMed Web of Science ®Google Scholar
• Bowen RL, Duffy SW, Ryan DA, et al. Early onset of breast cancer in a group of British black women. Br J Cancer. 2008 Jan;98(2):277–281.
   PubMed Web of Science ®Google Scholar
• Lund MJ, Trivers KF, Porter PL, et al. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat. 2009 Jan;113(2):357–370.
   PubMed Web of Science ®Google Scholar
• Lee A, Djamgoz MBA. Triple negative breast cancer: emerging therapeutic modalities and novel combination therapies. Cancer Treat Rev. 2018 Jan;62:110–122.
   PubMed Web of Science ®Google Scholar
• Badve S, Dabbs DJ, Schnitt SJ, et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol. 2011 Feb;24(2):157–167.
   PubMed Web of Science ®Google Scholar
• Jitariu AA, Cîmpean AM, Ribatti D, et al. Triple negative breast cancer: the kiss of death. Oncotarget. 2017 Jul;8(28):46652–46662.
   PubMedGoogle Scholar
• Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001 Sep;98(19):10869–10874.
   PubMed Web of Science ®Google Scholar
• Criscitiello C, Esposito A, Trapani D, et al. Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer. Cancer Treat Rev. 2016 Nov;50:205–207.
   PubMed Web of Science ®Google Scholar
• Cimino-Mathews A, Thompson E, Taube JM, et al. PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. Hum Pathol. 2016 Jan;47(1):52–63.
   PubMed Web of Science ®Google Scholar
• Beckers RK, Selinger CI, Vilain R, et al. Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Histopathology. 2016 Jul;69(1):25–34.
   PubMed Web of Science ®Google Scholar
• Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-Paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018 Nov;379(22):2108–2121.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016 Nov;375(19):1823–1833.
   PubMed Web of Science ®Google Scholar
• Ribas A, Hu-Lieskovan S. What does PD-L1 positive or negative mean? J Exp Med. 2016 Dec;213(13):2835–2840.
   PubMed Web of Science ®Google Scholar
• Marra A, Viale G, Curigliano G. Recent advances in triple negative breast cancer: the immunotherapy era. BMC Med. 2019 May;17(1):90.
   PubMed Web of Science ®Google Scholar
• Biswas T, Efird JT, Prasad S, et al. The survival benefit of neoadjuvant chemotherapy and pCR among patients with advanced stage triple negative breast cancer. Oncotarget. 2017 Dec;8(68):112712–112719.
   PubMedGoogle Scholar
• Dieci MV, Criscitiello C, Goubar A, et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol. 2014 Mar;25(3):611–618.
   PubMed Web of Science ®Google Scholar
• Lee JS, Yost SE, Yuan Y. Neoadjuvant treatment for triple negative breast cancer: recent progresses and challenges. Cancers (Basel). 2020 May;12(6)2–20.
   Web of Science ®Google Scholar
• Gil Del Alcazar CR, Huh SJ, Ekram MB, et al. Immune escape in breast cancer during in situ to invasive carcinoma transition. Cancer Discov. 2017 Oct;7(10):1098–1115.
   PubMed Web of Science ®Google Scholar
• Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020 Feb;382(9):810–821.
   PubMed Web of Science ®Google Scholar
• Ström CE, Johansson F, Uhlén M, et al. Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate. Nucleic Acids Res. 2011 Apr;39(8):3166–3175.
   PubMed Web of Science ®Google Scholar
• Curtin NJ, Szabo C. Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Mol Aspects Med. 2013 Dec;34(6):1217–1256.
   PubMed Web of Science ®Google Scholar
• Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010 Jul;376(9737):235–244.
   PubMed Web of Science ®Google Scholar
• Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017 Aug;377(6):523–533.
   PubMed Web of Science ®Google Scholar
• Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018 Aug;379(8):753–763.
   PubMed Web of Science ®Google Scholar
• Ettl J, Quek RGW, Lee KH, et al. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann Oncol. 2018 Sep;29(9):1939–1947.
   PubMed Web of Science ®Google Scholar
• Diéras V, Han HS, Kaufman B, et al. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020 Oct;21(10):1269–1282.
   PubMed Web of Science ®Google Scholar
• Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008 Mar;26(8):1275–1281.
   PubMed Web of Science ®Google Scholar
• Litton JK, Scoggins ME, Hess KR, et al. Neoadjuvant Talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant. J Clin Oncol. 2020 Feb;38(5):388–394.
   PubMed Web of Science ®Google Scholar
• McAndrew N, DeMichele A. Neoadjuvant chemotherapy considerations in triple-negative breast cancer. J Target Ther Cancer. 2018 Feb;7(1):52–69.
   PubMedGoogle Scholar
• Loibl S, O’Shaughnessy J, Untch M, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018 Apr;19(4):497–509.
   PubMed Web of Science ®Google Scholar
• Reaper PM, Griffiths MR, Long JM, et al. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol. 2011 Apr;7(7):428–430.
   PubMed Web of Science ®Google Scholar
• Yap TA, Luken M, O’Carrigan B, et al. Abstract PR14: phase I trial of first-in-class ataxia telangiectasia-mutated and Rad3-related (ATR) inhibitor VX-970 as monotherapy (mono) or in combination with carboplatin (CP) in advanced cancer patients (pts) with preliminary evidence of target modulation and antitumor activity. Mol Cancer Ther. 2015;14(12Supplement 2):PR14 %! Abstract PR14: Phase I trial of first-in-class ataxia telangiectasia-mutated and Rad13-related (ATR) inhibitor VX-970 as monotherapy (mono) or in combination with carboplatin (CP) in advanced cancer patients (pts) with preliminary evidence of target modulation and antitumor activity.
   PubMedGoogle Scholar
• Vendetti FP, Lau A, Schamus S, et al. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo. Oncotarget. 2015;6(42):44289–44305%44288 Dec %! The orally active and bioavailable ATR kinase inhibitor AZD46738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo %@ 41949-42553.
   Google Scholar
• Kwok M, Davies N, Agathanggelou A, et al. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells. Blood. 2016;127(5):582–595%587 2015/2011/2012 %2018 Feb %! ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP2053- or ATM-defective chronic lymphocytic leukemia cells %@ 1528-0020.
   PubMed Web of Science ®Google Scholar
• Peasland A, Wang LZ, Rowling E, et al. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. Br J Cancer. 2011 Jul;105(3):372–381.
   PubMed Web of Science ®Google Scholar
• Telli ML, Lord S, Dean E, et al. Abstract OT2-07-07: ATR inhibitor M6620 (formerly VX-970) with cisplatin in metastatic triple-negative breast cancer: preliminary results from a phase 1 dose expansion cohort (NCT02157792). Cancer Res. 2018;78(4 Supplement):OT2-07-07-OT02-07-07%! Abstract OT02-07-07: ATR inhibitor M6620 (formerly VX-6970) with cisplatin in metastatic triple-negative breast cancer: Preliminary results from a phase 6621 dose expansion cohort (NCT02157792).
   Web of Science ®Google Scholar
• Tu X, Kahila MM, Zhou Q, et al. ATR inhibition is a promising radiosensitizing strategy for triple-negative breast cancer. Mol Cancer Ther. 2018 Nov;17(11):2462–2472.
   PubMed Web of Science ®Google Scholar
• Kim D, Liu Y, Oberly S, et al. ATR-mediated proteome remodeling is a major determinant of homologous recombination capacity in cancer cells. Nucleic Acids Res. 2018;46(16):8311–8325%8318 8309 %! ATR-mediated proteome remodeling is a major determinant of homologous recombination capacity in cancer cells %@ 1362-4962.
   Web of Science ®Google Scholar
• Yap TA, Krebs MG, Postel-Vinay S, et al. Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers. Eur J Cancer. 2016;69: S2%! Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad6733-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers %@ 0959-8049.
   Web of Science ®Google Scholar
• Brandsma I, Fleuren EDG, Williamson CT, et al. Directing the use of DDR kinase inhibitors in cancer treatment. Expert Opin Investig Drugs. 2017;26(12):1341–1355%1347 2017/1310/1314 %1348 Dec %! Directing the use of DDR kinase inhibitors in cancer treatment %@ 1744-7658.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Hunter T. Roles of Chk1 in cell biology and cancer therapy. Int J Cancer. 2014;134(5):1013–1023%1017 2013/1005/1028 %1018 Mar %! Roles of Chk1011 in cell biology and cancer therapy %@ 1097-0215.
   Web of Science ®Google Scholar
• Patil M, Pabla N, Dong Z. Checkpoint kinase 1 in DNA damage response and cell cycle regulation. Cell Mol Life Sci. 2013;70(21):4009–4021%4007 2013/4003/4019 %4008 Nov %! Checkpoint kinase 4001 in DNA damage response and cell cycle regulation %@ 1420-9071.
   PubMed Web of Science ®Google Scholar
• Toledo LI, Murga M, Fernandez-Capetillo O. Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs. Mol Oncol. 2011;5(4):368–373%367 2011/2007/2028 %2018 Aug %! Targeting ATR and Chk2011 kinases for cancer treatment: a new model for new (and old) drugs %@ 1878-0261.
   PubMed Web of Science ®Google Scholar
• Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. 2017;17(2):93–115%118 101 %! Cell cycle proteins as promising targets in cancer therapy %@ 1474-1768.
   PubMed Web of Science ®Google Scholar
• De Witt Hamer PC, Mir SE, Noske D, et al. WEE1 Kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe: figure 1. Clin Cancer Res. 2011;17(13):4200–4207%4207 2011/4205/4211 %4208 Jul %! WEE4201 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe %@ 1078-0432.
   PubMed Web of Science ®Google Scholar
• Yoshida T, Tanaka S, Mogi A, et al. The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer. Ann Oncol. 2004;15(2):252–256%258 Feb %! The clinical significance of Cyclin B251 and Wee251 expression in non-small-cell lung cancer %@ 0923-7534.
   PubMed Web of Science ®Google Scholar
• Kiviharju-af Hällström TM, Jäämaa S, Mönkkönen M, et al. Human prostate epithelium lacks Wee1A-mediated DNA damage-induced checkpoint enforcement. Proc Natl Acad Sci U S A. 2007;104(17):7211–7216%7217 2007/7204/7212 %7218 Apr %! Human prostate epithelium lacks Wee7211A-mediated DNA damage-induced checkpoint enforcement %@ 0027-8424.
   PubMed Web of Science ®Google Scholar
• Backert S, Gelos M, Kobalz U, et al. Differential gene expression in colon carcinoma cells and tissues detected with a cDNA array. Int J Cancer. 1999;82(6):868–874%868 Sep %! Differential gene expression in colon carcinoma cells and tissues detected with a cDNA array %@ 0020-7136.
   PubMed Web of Science ®Google Scholar
• Lescarbeau RS, Lei L, Bakken KK, et al. Quantitative phosphoproteomics reveals Wee1 Kinase as a therapeutic target in a model of proneural Glioblastoma. Mol Cancer Ther. 2016;15(6):1332–1343%1337 2016/1305/1317 %1338 1306 %! Quantitative Phosphoproteomics Reveals Wee1331 Kinase as a Therapeutic Target in a Model of Proneural Glioblastoma %@ 1538-8514.
   PubMed Web of Science ®Google Scholar
• Aarts M, Bajrami I, Herrera-Abreu MT, et al. Functional genetic screen identifies increased sensitivity to WEE1 inhibition in cells with defects in Fanconi Anemia and HR pathways. Mol Cancer Ther. 2015;14(4):865–876%867 2015/2002/2011 %2018 Apr %! Functional Genetic Screen Identifies Increased Sensitivity to WEE2011 Inhibition in Cells with Defects in Fanconi Anemia and HR Pathways %@ 1538-8514.
   PubMed Web of Science ®Google Scholar
• Arora R, Joshi K, Nijhawan R, et al. Angiogenesis as an independent prognostic indicator in node-negative breast cancer. Anal Quant Cytol Histol. 2002 Aug;24(4):228–233.
   PubMedGoogle Scholar
• Uzzan B, Nicolas P, Cucherat M, et al. Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res. 2004 May;64(9):2941–2955.
   PubMed Web of Science ®Google Scholar
• Salven P, Perhoniemi V, Tykkä H, et al. Serum VEGF levels in women with a benign breast tumor or breast cancer. Breast Cancer Res Treat. 1999 Jan;53(2):161–166.
   PubMed Web of Science ®Google Scholar
• Hervé MA, Buteau-Lozano H, Vassy R, et al. Overexpression of vascular endothelial growth factor 189 in breast cancer cells leads to delayed tumor uptake with dilated intratumoral vessels. Am J Pathol. 2008 Jan;172(1):167–178.
   PubMed Web of Science ®Google Scholar
• Linderholm BK, Hellborg H, Johansson U, et al. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol. 2009 Oct;20(10):1639–1646.
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007 Dec;357(26):2666–2676.
   PubMed Web of Science ®Google Scholar
• Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005 Feb;23(4):792–799.
   PubMed Web of Science ®Google Scholar
• Earl HM, Hiller L, Dunn JA, et al. Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. Lancet Oncol. 2015 Jun;16(6):656–666.
   PubMed Web of Science ®Google Scholar
• Brufsky A, Valero V, Tiangco B, et al. Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. Breast Cancer Res Treat. 2012 Jun;133(3):1067–1075.
   PubMed Web of Science ®Google Scholar
• Von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med. 2012 Jan;366(4):299–309.
   PubMed Web of Science ®Google Scholar
• Nahleh ZA, Barlow WE, Hayes DF, et al. SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat. 2016 Aug;158(3):485–495.
   PubMed Web of Science ®Google Scholar
• Bell R, Brown J, Parmar M, et al. Final efficacy and updated safety results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer. Ann Oncol. 2017 Apr;28(4):754–760.
   PubMed Web of Science ®Google Scholar
• Davidson NE, Gelmann EP, Lippman ME, et al. Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol Endocrinol. 1987 Mar;1(3):216–223.
   PubMedGoogle Scholar
• Li XR, Liu M, Zhang YJ, et al. CK5/6, EGFR, Ki-67, cyclin D1, and nm23-H1 protein expressions as predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients. Med Oncol. 2011 Dec;28(Suppl S1):S129–134.
   PubMedGoogle Scholar
• Cerqueira OL, Truesdell P, Baldassarre T, et al. CIP4 promotes metastasis in triple-negative breast cancer and is associated with poor patient prognosis. Oncotarget. 2015 Apr;6(11):9397–9408.
   PubMedGoogle Scholar
• Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer. 2007 Jan;109(1):25–32.
   PubMed Web of Science ®Google Scholar
• Carey LA, Rugo HS, Marcom PK, et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 2012 Jul;30(21):2615–2623.
   PubMed Web of Science ®Google Scholar
• Baselga J, Gómez P, Greil R, et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol. 2013 Jul;31(20):2586–2592.
   PubMed Web of Science ®Google Scholar
• Crozier JA, Advani PP, LaPlant B, et al. N0436 (Alliance): a Phase II trial of Irinotecan with Cetuximab in patients with metastatic breast cancer previously exposed to anthracycline and/or Taxane-containing therapy. Clin Breast Cancer. 2016 Feb;16(1):23–30.
   PubMed Web of Science ®Google Scholar
• Yardley DA, Ward PJ, Daniel BR, et al. Panitumumab, Gemcitabine, and Carboplatin as treatment for women with metastatic triple-negative breast cancer: a Sarah cannon research institute Phase II trial. Clin Breast Cancer. 2016 Oct;16(5):349–355.
   PubMed Web of Science ®Google Scholar
• Nabholtz JM, Chalabi N, Radosevic-Robin N, et al. Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer. Int J Cancer. 2016 May;138(9):2274–2280.
   PubMed Web of Science ®Google Scholar
• Bernsdorf M, Ingvar C, Jörgensen L, et al. Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial. Breast Cancer Res Treat. 2011 Apr;126(2):463–470.
   PubMed Web of Science ®Google Scholar
• Delaloge S, DeForceville L. Targeting PI3K/AKT pathway in triple-negative breast cancer. Lancet Oncol. 2017 Oct;18(10):1293–1294.
   PubMed Web of Science ®Google Scholar
• Fouque A, Jean M, Weghe P, et al. Review of PI3K/mTOR inhibitors entering clinical trials to treat triple negative breast cancers. Recent Pat Anticancer Drug Discov. 2016;11(3):283–296.
   PubMed Web of Science ®Google Scholar
• Gordon V, Banerji S. Molecular pathways: PI3K pathway targets in triple-negative breast cancers. Clin Cancer Res. 2013 Jul 15;19(14):3738–3744.
   PubMed Web of Science ®Google Scholar
• Khan MA, Jain VK, Rizwanullah M, et al. PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges. Drug Discov Today. 2019 Nov;24(11):2181–2191.
   PubMed Web of Science ®Google Scholar
• Massihnia D, Galvano A, Fanale D, et al. Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway. Oncotarget. 2016 Sep 13;7(37):60712–60722.
   PubMedGoogle Scholar
• Basho RK, Gilcrease M, Murthy RK, et al. Targeting the PI3K/AKT/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer: evidence from a Phase 1 trial of mTOR inhibition in combination with Liposomal Doxorubicin and Bevacizumab. JAMA Oncol. 2017 Apr 1;3(4):509–515.
   PubMed Web of Science ®Google Scholar
• Singh J, Novik Y, Stein S, et al. Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer. Breast Cancer Res. 2014 Mar 31;16(2):R32.
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Abramson VG, Sanders ME, et al. TBCRC 032 IB/II multicenter study: molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR(+) metastatic triple-negative breast cancer. Clin Cancer Res. 2020 May 1;26(9):2111–2123.
   PubMed Web of Science ®Google Scholar
• Garrido-Castro AC, Saura C, Barroso-Sousa R, et al. Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. Breast Cancer Res. 2020 Nov 2;22(1):120.
   PubMed Web of Science ®Google Scholar